Search results
Results from the WOW.Com Content Network
NEW YORK (Reuters) -Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday. Sanofi did ...
And in 2022, in a lawsuit brought by other plaintiffs in another Zantac case, a U.S. federal court judge ruled “the plaintiffs had no reliable evidence.” Sanofi acquired Zantac in 2017. Before ...
Citi analysts estimate GSK will settle all the Zantac cases against it for a total of about $5 billion in the first quarter of 2024, clearing what it called a "still relevant" overhang for its ...
Medinilla is presiding over the majority of the nearly 80,000 cases still pending in the United States over Zantac, which was once the world's top-selling drug.
Zantac was first marketed in 1981, [7] and it was described in 1989 as "one of the most expensive drugs on the market", [8] and "the world's biggest-selling prescription drug". [9] Addiction to taking it ("a habit") was how some of its users described Zantac. [ 10 ]
GSK said the terms of the settlement were confidential and that it did not admit to any liability. ... GSK still faced about 79,000 cases related to Zantac in the United States, with 73,000 of ...
The drugmaker has settled a series of lawsuits related to Zantac over the past 12 months, including several in California. ... Former Zantac makers GSK, Pfizer, Sanofi and Boehringer Ingelheim are ...
(Reuters) -Pfizer has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people ...